Osman Moneer Profile Banner
Osman Moneer Profile
Osman Moneer

@osmanmoneer

Followers
255
Following
405
Media
4
Statuses
50

he/him/his. Current @StanfordMed Internal Medicine Resident. Formerly @YaleMed , @Columbia .

Joined February 2020
Don't wanna be here? Send us removal request.
Explore trending content on Musk Viewer
Pinned Tweet
@osmanmoneer
Osman Moneer
7 months
We’re moving to California! So excited to match at @StanfordDeptMed for Internal Medicine residency!!
Tweet media one
Tweet media two
49
209
5K
@osmanmoneer
Osman Moneer
3 years
Had an amazing time yesterday riding my first century for @CTFRide @YaleCancer ! Couldn’t have asked for better company @shinmeichan @original_jz @jrwoodbridge @PeterNatov
Tweet media one
0
4
26
@osmanmoneer
Osman Moneer
4 years
As we recently saw with the United States's initial response to Covid-19, single-sourced diagnostic tests hamper clinical practice. For more on innovation policy for diagnostics, check out my paper with @WNicholsonPrice and Chaaru Deb in @J_Law_Biosci !
Tweet media one
1
8
21
@osmanmoneer
Osman Moneer
1 year
How can FDA & CMS align policies to ensure that medical device innovation is based on strong and representative evidence? In a new @JAMACardio Special Communication, we explore market authorization and coverage for Breakthrough cardiovascular🫀 devices.
Tweet media one
1
7
21
@osmanmoneer
Osman Moneer
4 years
Check out our paper on vaccine development and regulation! We reviewed current and potential approaches to the FDA's regulation of vaccines. To contextualize the assessment of Covid-19 vaccines, we looked at all new vaccines approved in the last 15 yrs.
0
6
16
@osmanmoneer
Osman Moneer
3 years
Interested in learning about the performance of FDA postmarketing studies? In our new paper, we synthesize evidence from the academic literature and gov reports to assess the track record of postmarketing requirements and commitments. @PORTAL_Research
0
5
16
@osmanmoneer
Osman Moneer
3 years
Check out our paper on postmarketing studies for new vaccines! We found that vaccine postmarketing studies had a lengthy time to completion, highlighting the importance of ensuring that Covid-19 vaccine PMRs/PMCs are completed in a timely fashion. @akesselheim @PORTAL_Research
@JAMANetworkOpen
JAMA Network Open
3 years
Among postmarket commitments (PMCs) and postmarket requirements (PMRs) attached to new vaccines approved in the last 15 years, only about half were considered fulfilled in 2020 and the time to completion was a median of over 4 years.
0
1
4
0
5
12
@osmanmoneer
Osman Moneer
4 years
Spent this morning helping facilitate a discussion with the incoming M1 class on @DorothyERoberts 's Fatal Invention, which deconstructs biological race. Thanks to my classmates @ellelandegife , @c_ijeli , @nobles_autumn , and @maituranci for organizing such a great session!
1
3
7
@osmanmoneer
Osman Moneer
4 years
And as a personal milestone, this was my first paper in medical school!
0
0
4
@osmanmoneer
Osman Moneer
4 years
Was exciting to hear @DorothyERoberts herself speak at the end of the session, and I'd highly recommend reading her book and associated scholarship.
2
0
4
@osmanmoneer
Osman Moneer
3 years
Great work from @jamiesonomarr and @shinmeichan quantifying the differential burnout between URIM vs non-URIM students!
@JAMANetworkOpen
JAMA Network Open
3 years
In a survey, underrepresented minority medical students reported experiencing higher levels of exhaustion-related burnout compared with their peers, especially if they experienced racial discrimination during training @DowinHugh @shinmeichan @jamiesonomarr
0
5
14
0
0
4
@osmanmoneer
Osman Moneer
1 year
Fortunate to have worked with such an amazing team of co-authors!! Kudos to Vinay Rathi ( @MassEyeAndEar ), @JLJohnstonMD ( @BrighamMedRes ), @jsross119 ( @Yale_CRRIT ), and Sanket Dhruva ( @UCSFCardiology )
0
0
3
@osmanmoneer
Osman Moneer
1 year
Along with an editor's note from @JAMACardio 's @NMHheartdoc , Patrick O'Gara, and Robert Bonow contextualizing our work:
1
1
3
@osmanmoneer
Osman Moneer
4 years
For similar work (and a shorter read) by Professor Roberts, check out her article "Taking race out of human genetics" in Science. I'd especially encourage other genomic researchers to read and reflect on the problematic use of race in genetic research.
0
0
3
@osmanmoneer
Osman Moneer
3 years
4/5 Regulatory gaps exist surrounding oversight as most companies that make DTC-PGTs are not considered to be HIPAA-covered entities (or business associates), which allows them to avoid the mainstay of US health data regulation.
1
0
2
@osmanmoneer
Osman Moneer
3 years
3/5 But despite these benefits, DTC-PGTs present current and future risks for data control, agency and discrimination. Moreover, recent high-profile mergers—such as that of Virgin Group and 23andMe— could potentially change company privacy policies and heighten these concerns.
1
0
2
@osmanmoneer
Osman Moneer
3 years
2/5 DTC-PGTs are exciting because they provide interesting health information (like disease susceptibility) to consumers in addition to their ancestry and genealogy offerings. They also support the development of personalized medicines by accelerated drug discovery.
1
0
2
@osmanmoneer
Osman Moneer
3 years
5/5 We explore policy solutions that bring DTC-PGT companies under the umbrella of HIPAA regulations to ensure better consumer protection surrounding their use. For more, check out the full Comment!
0
0
1